Sugammadex as a reversal agent for neuromuscular block: An evidence-based review

Core Evidence

Volumn 8, Issue , 2013, Pages 57-67

  Schaller, Stefan Josef ^a,b   Fink, Heidrun ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cyclodextrin; PORC; Reversal agent; SRBAs

Indexed keywords

ATRACURIUM BESILATE; CISATRACURIUM; FUSIDIC ACID; MIVACURIUM; PANCURONIUM; PROGESTERONE; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; TOREMIFENE; VECURONIUM;

ANESTHESIA INDUCTION; ATRIOVENTRICULAR BLOCK; BLEEDING; BREAST FEEDING; CESAREAN SECTION; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; ELECTROCONVULSIVE THERAPY; ENDOTRACHEAL INTUBATION; EVIDENCE BASED PRACTICE; GENERAL ANESTHESIA; HEART ARREST; HUMAN; HYPERKALEMIA; INTERNATIONAL NORMALIZED RATIO; MULTICENTER STUDY (TOPIC); MULTIPLE DRUG DOSE; MYALGIA; MYASTHENIA GRAVIS; NEUROMUSCULAR BLOCKING; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PREGNANT WOMAN; PROTHROMBIN TIME; QT PROLONGATION; RAPID SEQUENCE INDUCTION; RECOMMENDED DRUG DOSE; REIMBURSEMENT; RESUSCITATION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 84885361383     PISSN: 1555175X     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S35675     Document Type: Review

References (114)

1. Murphy GS, Szokol J W, Marymont JH, Greenberg S.B., Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107(1):130-137.
2. Eikermann M, Blobner M, Groeben H., et al Postoperative upper airway obstruction after recovery of the train of four ratio of the adductor pollicis muscle from neuromuscular blockade. Anesth Analg. 2006; 102(3):937-942.
3. Sundman E, Witt H, Olsson R., Ekberg O, Kuylenstierna R, Eriksson LI The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology. 2000;92(4):977-984. (Pubitemid 30180973)
4. Berg H, Roed J, Viby-Mogensen J, et al Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997;41(9):1095-1103.
5. Combes X, Andriamifidy L, Dufresne E., et al Comparison of two induction regimens using or not using muscle relaxant: impact on postoperative upper airway discomfort. Br J Anaesth. 2007;99(2):276-281. (Pubitemid 47249401)
6. Mencke T, Echternach M, Kleinschmidt S., et al Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial. Anesthesiolog y. 2003;98(5):1049-1056. (Pubitemid 36520190)
7. Debaene B, Plaud B, Dilly M P, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98(5): 1042-1048. (Pubitemid 36520189)
8. Bom A, Hope F, Rutherford S., Thomson K. Preclinical pharmacology of sugammadex. J Crit Care. 2009;24(1):29-35.
9. Akha AS, Rosa J, Jahr J.S., Li A., Kiai K. Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions. Anesthesiol Clin. 2010;28(4):691-708.
10. Merck & Co Inc. BRIDION: E PA R - Product Information Annex I: Summary of product characteristics. European Medicines Agency; London, UK. 2013. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000885/WC500052310.pdf. Accessed June 13, 2013.
11. Peeters P, Passier P, Smeets J., et al Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharm Drug Dispos. 2011;32(3):159-167.
12. Staals LM, de Boer HD, van Egmond J, et al Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats. J Anesth. 2011;25(2):241-246.
13. Staals LM, Snoeck MM, Driessen J.J., Flockton EA, Heeringa M, Hunter JM Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br J Anaesth. 2008;101(4):492-497.
14. Staals LM, Snoeck MM, Driessen J.J., et al Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010;104(1):31-39.
15. Cammu G, Van Vlem B, van den Heuvel M, et al. Dialysability of sug-ammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth. 2012;109(3):382-390.
16. Duvaldestin P, Kuizenga K, Saldien V., et al A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg. 2010;110(1):74-82.
17. Suy K, Morias K, Cammu G., et al Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106(2):283-288. (Pubitemid 46185173)
18. Peeters PA, van den Heuvel M W, van Heumen E, et al. Safety, toler-ability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig. 2010;30(12):867-874.
19. de Boer H.D., Driessen JJ, Marcus M.A., Kerkkamp H., Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007;107(2):239-244. (Pubitemid 47196486)
20. Groudine SB, Soto R, Lien C., Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104(3):555-562.
21. Jones RK, Caldwell JE, Brull S.J., Soto RG Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008;109(5): 816-824.
22. Plaud B, Meretoja O, Hofmockel R., et al Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology. 2009;110(2):284-294.
23. Flockton EA, Mastronardi P, Hunter J.M., et al Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008;100(5):622-630. (Pubitemid 351774353)
24. Vanacker B.F., Vermeyen KM, Struys M.M., et al Reversal of rocuronium-induced neuromuscular block with the novel drug sugam-madex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg. 2007;104(3):563-568.
25. Sorgenfrei IF, Norrild K, Larsen P.B., et al Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104(4):667-674.
26. Pongrácz A., Szatmári S, Nemes R., Fülesdi B, Tassonyi E. Reversal of Neuromuscular Blockade with Sugammadex at the Reappearance of Four Twitches to Train-of-four Stimulation. Anesthesiology. 2013;119(1):36-42.
27. Schaller SJ, Fink H, Ulm K., Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthesiology. 2010;113(5):1054-1060.
28. Meretoja OA. Neuromuscular block and current treatment strategies for its reversal in children. Paediatr Anaesth. 2010;20(7):591-604.
29. McDonagh DL, Benedict PE, Kovac A.L., et al Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. Anesthesiology. 2011;114(2):318-329.
30. Suzuki T, Kitajima O, Ueda K., Kondo Y, Kato J, Ogawa S. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients. Br J Anaesth. 2011;106(6): 823-826.
31. Yoshida F, Suzuki T, Kashiwai A., Furuya T, Konishi J, Ogawa S. Correlation between cardiac output and reversibility of rocuronium-induced moderate neuromuscular block with sugammadex. Acta Anaesthesiol Scand. 2012;56(1):83-87.
32. Cammu G, Coart D, De Graeve K, Beelen R. Reversal of rocuronium-induced neuromuscular block with sugammadex in heart failure patients: a prospective observational study. Acta Anaesthesiol Belg. 2012;63(2):69-73.
33. Kadoi Y, Nishida A, Saito S. Recovery time after sugammadex reversal of rocuronium-induced muscle relaxation for electroconvulsive therapy is independent of cardiac output in both young and elderly patients. J ECT. 2013;29(1):33-36.
34. Meyhoff CS, Lund J, Jenstrup M.T., et al Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg. 2009;109(3):787-792.
35. Leykin Y, Pellis T, Lucca M., Lomangino G, Marzano B, Gullo A. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg. 2004;99(4):1086-1089. (Pubitemid 39287397)
36. de Baerdemaeker LEC, Mortier E P, Struys MMRF. Pharmacokinetics in obese patients. CEACCP. 2004;4(5):152-155.
37. -1 ideal body weight of rocuronium. Eur J Anaesthesiol. 2011;28(8):609-610.
38. Llauradó S, Sabaté A, Ferreres E, Camprubí I, Cabrera A. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology. 2012;117(1):93-98.
39. Van Lancker P., Dillemans B, Bogaert T., Mulier J P, De Kock M, Haspeslagh M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia. 2011;66(8): 721-725.
40. Schmartz D, Guerci P, Fuchs-Buder T. Sugammadex dosing in bariatric patients. Anesthesiolog y. 2013;118(3):754.
41. Carron M, Parotto E, Ori C. The use of sugammadex in obese patients. Can J Anaesth. 2012;59(3):321-322.
42. Carron M, Freo U, Parotto E., Ori C. The correct dosing regimen for sugammadex in morbidly obese patients. Anaesthesia. 2012;67(3): 298-299.
43. Sabaté A, Llauradó S. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia. 2012;67(6):682; author reply 682-683.
44. Le Corre F., Nejmeddine S, Fatahine C., Tayar C, Marty J, Plaud B. Recurarization after sugammadex reversal in an obese patient. Can J Anaesth. 2011;58(10):944-947.
45. Dewachter P, Mouton-Faivre C, Emala C W. Anaphylaxis and anesthesia: controversies and new insights. Anesthesiology. 2009;111(5): 1141-1150.
46. Baldo BA, McDonnell NJ, Pham NH Drug-specific cyclodextrins with emphasis on sugammadex, the neuromuscular blocker rocuronium and perioperative anaphylaxis: implications for drug allergy. Clin Exp Allerg y. 2011;41(12):1663-1678.
47. Clarke RC, Sadleir PH, Platt PR The role of sugammadex in the development and modification of an allergic response to rocuronium: evidence from a cutaneous model. Anaesthesia. 2012;67(3): 266-273.
48. Kawano T, Yokoyama M. Can sugammadex encapsulation eliminate the antigenic activity of aminosteroidal neuromuscular blocking agent? J Anesth. 2011;25(6):953-954.
49. Leysen J, Bridts CH, De Clerck LS, Ebo DG Rocuronium-induced anaphylaxis is probably not mitigated by sugammadex: evidence from an in vitro experiment. Anaesthesia. 2011;66(6):526-527.
50. Tomak Y, Yilmaz A, Bostan H., et al Effects of sugammadex and rocuronium mast cell number and degranulation in rat liver. Anaesthesia. 2012;67(10):1101-1104.
51. Barthel F, Stojeba N, Lyons G., Biermann C, Diemunsch P. Sugammadex in rocuronium anaphylaxis: dose matters. Br J Anaesth. 2012;109(4):646-647.
52. Motamed C, Baguenard P, Bourgain JL Possible mitigation of rocuronium-induced anaphylaxis after administration of sugammadex. J Anaesthesiol Clin Pharmacol. 2012;28(1):127-128.
53. Kawano T, Tamura T, Hamaguchi M., Yatabe T, Yamashita K, Yokoyama M. Successful management of rocuronium-induced ana-phylactic reactions with sugammadex: a case report. J Clin Anesth. 2012;24(1):62-64.
54. Funnell AE, Griffiths J, Hodzovic I. A further case of rocuronium-induced anaphylaxis treated with sugammadex. Br J Anaesth. 2011;107(2):275-276.
55. McDonnell NJ, Pavy TJ, Green L.K., Platt PR Sugammadex in the management of rocuronium-induced anaphylaxis. Br J Anaesth. 2011;106(2):199-201.
56. White P.F., Tufanogullari B, Sacan O., et al The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. Anesth Analg. 2009;108(3):846-851.
57. Clarke R, Sadleir P, Platt P. A reply. Anaesthesia. 2012;67(10):1175.
58. Perry JJ, Lee JS, Sillberg V.A., Wells GA Rocuronium versus succi-nylcholine for rapid sequence induction intubation [review]. Cochrane Database Syst Rev. 2008;2:CD002788.
59. McCahon R. Role of sugammadex in rapid sequence induction and intubation. Br J Anaesth. 2012;109(1):123; author reply 123-124.
60. Lee C, Jahr JS, Candiotti K.A., Warriner B., Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009;110(5): 1020-1025.
61. Sørensen MK, Bretlau C, Gätke MR, Sørensen AM, Rasmussen LS. Rapid sequence induction and intubation with rocuronium-sugammadex compared with succinylcholine: a randomized trial. Br J Anaesth. 2012;108(4):682-689.
62. Abrishami A, Ho J, Wong J., Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade [review]. Cochrane Database Syst Rev. 2009;4:CD007362.
63. Bisschops MM, Holleman C, Huitink JM Can sugammadex save a patient in a simulated 'cannot intubate, cannot ventilate' situation? Anaesthesia. 2010;65(9):936-941.
64. Ackerman AG, Russ S, Puttick N., Kessell G. Availability and storage of sugammadex for emergency use. Anaesthesia. 2011;66(2):139-140.
65. Dada A, Dunsire F. Can sugammadex save a patient in a simulated 'cannot intubate, cannot ventilate' scenario? Anaesthesia. 2011;66(2): 141-142.
66. Ezri T, Evron S. Sugammadex and the cannot intubate/cannot ventilate scenario in patients with predicted difficult airway (1). Letter 1. Br J Anaesth. 2012;109(3):459; author reply 459-462.
67. Telgarsky B, Stacey M. Sugammadex and the cannot intubate/cannot ventilate scenario in patients with predicted difficult airway (1). Letter 2. Br J Anaesth. 2012;109(3):459-460; author reply 461.
68. Watson SJ, Jefferson P, Ball DR Sugammadex and the cannot intubate/cannot ventilate scenario in patients with predicted difficult airway (1). Letter 3. Br J Anaesth. 2012;109(3):460-461; author reply 461.
69. Kyle BC, Gaylard D, Riley RH A persistent 'can't intubate, can't oxygenate' crisis despite rocuronium reversal with sugammadex. Anaesth Intensive Care. 2012;40(2):344-346.
70. Curtis R, Lomax S, Patel B. Use of sugammadex in a 'can't intubate, can't ventilate' situation. Br J Anaesth. 2012;108(4):612-614.
71. Abouleish E, Abboud T, Lechevalier T., Zhu J, Chalian A, Alford K. Rocuronium (Org 9426) for caesarean section. Br J Anaesth. 1994; 73(3):336-341. (Pubitemid 24267430)
72. Nauheimer D, Kollath C, Geldner G. Modified rapid sequence induction for Caesarian sections: case series on the use of rocuronium and sugammadex. Anaesthesist. 2012;61(8):691-695. German.
73. Pühringer F.K., Kristen P, Rex C. Sugammadex reversal of rocuronium-induced neuromuscular block in Caesarean section patients: a series of seven cases. Br J Anaesth. 2010;105(5):657-660.
74. Williamson RM, Mallaiah S, Barclay P. Rocuronium and sugammadex for rapid sequence induction of obstetric general anaesthesia. Acta Anaesthesiol Scand. 2011;55(6):694-699.
75. Kadoi Y, Hoshi H, Nishida A., Saito S. Comparison of recovery times from rocuronium-induced muscle relaxation after reversal with three different doses of sugammadex and succinylcholine during electrocon-vulsive therapy. J Anesth. 2011;25(6):855-859.
76. Unterbuchner C, Fink H, Blobner M. The use of sugammadex in a patient with myasthenia gravis. Anaesthesia. 2010;65(3):302-305.
77. Petrun AM, Mekis D, Kamenik M. Successful use of rocuronium and sugammadex in a patient with myasthenia. Eur J Anaesthesiol. 2010;27(10):917-918.
78. de Boer H.D., van Egmond J, Driessen JJ, Booij LH Sugammadex in patients with myasthenia gravis. Anaesthesia. 2010;65(6):653.
79. Rudzka-Nowak A., Piechota M. Anaesthetic management of a patient with myasthenia gravis for abdominal surgery using sugammadex. Arch Med Sci. 2011;7(2):361-364.
80. Garcia V, Diemunsch P, Boet S. Use of rocuronium and sugammadex for caesarean delivery in a patient with myasthenia gravis. Int J Obstet Anesth. 2012;21(3):286-287.
81. Suzuki T, Nameki K, Shimizu H., Shimizu Y, Nakamura R, Ogawa S. Efficacy of rocuronium and sugammadex in a patient with dermatomyositis. Br J Anaesth. 2012;108(4):703.
82. de Boer H.D., van Esmond J, Booij LH, Driessen JJ Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy. Paediatr Anaesth. 2009;19(12): 1226-1228.
83. Baumgartner P. Rocuronium and sugammadex in myotonic dystrophy. Anaesth Intensive Care. 2010;38(5):959-960.
84. Kashiwai A, Suzuki T, Ogawa S. Sensitivity to rocuronium-induced neuromuscular block and reversibility with sugammadex in a patient with myotonic dystrophy. Case Rep Anesthesiol. 2012;2012:107952.
85. Matsuki Y, Hirose M, Tabata M., Nobukawa Y, Shigemi K. The use of sugammadex in a patient with myotonic dystrophy. Eur J Anaesthesiol. 2011;28(2):145-146.
86. Petrovski J. The use of sugammadex to reverse rocuronium in a patient with myotonic dystrophy. Anaesth Intensive Care. 2011;39(3): 505-506.
87. Stewart PA, Phillips S, de Boer HD. Residual neuromuscular blockade in myotonic dystrophy: lessons unlearned and sugammadex. Anaesth Intensive Care. 2011;39(4):756-757; author reply 757.
88. Stewart PA, Phillips S, De Boer HD. Sugammadex reversal of rocuronium-induced neuromuscular blockade in two types of neuro-muscular disorders: Myotonic dystrophy and spinal muscular atrophy. Rev Esp Anestesiol Reanim. 2013;60(4):226-229.
89. Vilela H, Santos J, Colaço J, Oliveira E., Canas-da-Silva P. Reversal of neuromuscular blockade with sugammadex in a patient with spinal muscular atrophy type III (Kugelberg-Welander syndrome). J Anesth. 2012;26(2):306-307.
90. Kelsaka E, Karakaya D, Zengin EC Use of sugammadex in a patient with amyotrophic lateral sclerosis. Med Princ Pract. 2013;22(3):304-306.
91. Sparr HJ, Vermeyen KM, Beaufort A.M., et al Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiolog y. 2007;106(5):935-943. (Pubitemid 46684059)
92. Cammu G, De Kam PJ, Demeyer I, et al Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth. 2008;100(3):373-379. (Pubitemid 351773650)
93. Dahl V, Pendeville PE, Hollmann M W, Heier T, Abels E.A., Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing non-cardiac surgery. Eur J Anaesthesiol. 2009;26(10):874-884.
94. de Kam P.J., van Kuijk J, Prohn M, Thomsen T., Peeters P. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig. 2010;30(9):599-611.
95. de Kam P.J., van Kuijk J, Smeets J, Thomsen T., Peeters P. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study. Int J Clin Pharmacol Ther. 2012;50(8):595-604.
96. Soria A, Motamed C, Gaouar H., Chemam S, Amsler E, Francès C. Severe reaction following sugammadex injection: hypersensitivity? J Investig Allergol Clin Immunol. 2012;22(5):382.
97. Godai K, Hasegawa-Moriyama M, Kuniyoshi T., et al Three cases of suspected sugammadex-induced hypersensitivity reactions. Br J Anaesth. 2012;109(2):216-218.
98. Kokki M, Ali M, Turunen M., Kokki H. Suspected unexpected adverse effect of sugammadex: hypotension. Eur J Clin Pharmacol. 2012;68(5):899-900.
99. Menéndez-Ozcoidi L., Ortiz-Gómez JR, Olaguibel-Ribero JM, Salvador-Bravo MJ. Allergy to low dose sugammadex. Anaesthesia. 2011;66(3):217-219.
100. Chambers D, Paulden M, Paton F., et al Sugammadex for reversal of neu-romuscular block after rapid sequence intubation: a systematic review and economic assessment. Br J Anaesth. 2010;105(5):568-575.
101. Lingle CJ, Steinbach JH Neuromuscular blocking agents. Int Anesthesiol Clin. 1988;26(4):288-301. (Pubitemid 19001459)
102. Zwiers A, van den Heuvel M, Smeets J, Rutherford S. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic- pharmacodynamic modelling approach. Clin Drug Investig. 2011;31(2):101-111.
103. Fabregat-López J, Veiga-Ruiz G, Dominguez-Serrano N, García-Martinez MR. Re-establishment of neuromuscular block by rocuronium after sugammadex administration. Can J Anaesth. 2011;58(7):658-659.
104. Harris P. Unexpected failure of rocuronium-mediated neuromuscular blockade. Anaesthesia. 2011;66(6):525; author reply 525-525; author reply 526.
105. Cammu G, de Kam PJ, De Graeve K, et al Repeat dosing of rocuro-nium 1.2 mg kg-1 after reversal of neuromuscular block by sugamma-dex 4.0 mg kg-1 in anaesthetized healthy volunteers: a modelling-based pilot study. Br J Anaesth. 2010;105(4):487-492.
106. healthcarebluebook.com [homepage on the Internet]. Cholecys-tectomy (laparoscopic). Health Care Blue Book; 2013. Available from: http://www.healthcarebluebook.com/page-Results.aspx?id=74&dataset=MD. Accessed June 10, 2013.
107. Berry M, Martin J, Geldner G., et al Analyse der IST-kosten Anäshtesie in deutschen krankenhäusern. [Analysis of actual costs of anesthesia in German Hospitals] Klinikum Ludwigsburg. 2007;48(3):140-146. German. (Pubitemid 46568660)
108. Ministry of Health, Labour and Welfare (Japan). Fee Regulation for General Anesthesia. Tokyo: Ministry of Health, Labour and Welfare (Japan); 2013. Available from: http://www.mhlw.go.jp/stf/shingi/2r9852000001va4h-att/ 2r9852000001vak5.pdf. Accessed June 10, 2013. Japanese.
109. Paton F, Paulden M, Chambers D., et al Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth. 2010;105(5):558-567.
110. Cammu G.V., Smet V, De Jongh K, Vandeput D. A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery. Anaesth Intensive Care. 2012;40(6):999-1006.
111. Ledowski T, Hillyard S, Kozman A., et al Unrestricted access to sugammadex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. Anaesth Intensive Care. 2012;40(2):340-343.
112. Chambers D, Paulden M, Paton F., et al Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess. 2010;14(39):1-211.
113. Kopman A.F. Neostigmine versus sugammadex: which, when, and how much? Anesthesiology. 2010;113(5):1010-1011.
114. Raft J, Chenot ED, Longrois D, Meistelman C. Analysis of neuro-muscular blocking drugs and sugammadex expenses, one year after its introduction into routine clinical practice. Ann Fr Anesth Reanim. 2011;30(10):758-759. French.